Lacidipine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: April 10, 2026

Lacidipine

Dihydropyridine Derivatives

GB MHRA

Drug class: Dihydropyridine Derivatives
Availability: See label
Markets covered: 1
Products on record: 12

C08CADihydropyridine Derivatives

Overview

Lacidipine is an active pharmaceutical ingredient in the Dihydropyridine Derivatives group (C08CA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	12	April 10, 2026

GBUnited Kingdom· MHRA

12 products

Uses

GBOfficial regulatory label· revised April 10, 2026[1]

Lacidipine is indicated in adults for the treatment of hypertension either alone or in combination with other antihypertensive agents, including ß- adrenoceptor antagonists, diuretics, and ACE-inhibitors.

How to take

Sources & citations

[1]MHRA (UK) · PL045691494 · revised April 10, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised April 10, 2026[1]

Lacidipine is generally well tolerated. Some individuals may experience minor side effects which are related to its known pharmacological action of peripheral vasodilation. Such effects, indicated by a hash (#), are usually transient and usually disappear with continued administration of lacidipine at the same dosage.
Very common (≥1/10) Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100) Rare (≥1/10,000 to <1/1000) Very rare (<1/10,000) Not know n (cann ot be estima ted from the availa ble data) Psychiatric disorders Depression Nervous system disorders Dizziness#, Headache# Tremor Cardiac disorders Palpitations#, Tachycardia Syncope, Angina pectoris Vascular disorders Flushing# Hypotension Gastrointestinal disorders Abdominal discomfort, Nausea Gingival hyperplasia Skin and subcutaneous tissue disorders Rash, Erythema, Pruritus Angioedema, Urticaria Musculoskeletal and connective tissue disorders Muscle cramps Renal and urinary disorders Polyuria General disorders and administration site conditions Asthenia, Oedema# Investigations Blood alkaline phosphatase increased As with other dihydropyridines aggravation of underlying angina pectoris has been reported in a small number of individuals, especially at the start of treatment.
This is more likely to happen in patients with symptomatic ischaemic heart disease. Lacidipine should be discontinued under medical supervision in patients who develop unstable angina.
Reporting of suspected adverse reactions in UK:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.

GBOfficial regulatory label· Warnings and precautions· revised April 10, 2026[1]

In specialised studies lacidipine has been shown not to affect the spontaneous function of the SA node or to cause prolonged conduction within the AV node. However, the theoretical potential for a calcium antagonist to affect the activity of the SA and AV nodes should be noted, and therefore lacidipine should be used with caution in patients with pre-existing abnormalities in the activity of the SA and AV nodes.
As has been reported with other dihydropyridine calcium channel antagonists, lacidipine should be used with caution in patients with congenital or documented acquired QT prolongation. g. g. terfenadine). As with other calcium antagonists, lacidipine should be used with caution in patients with poor cardiac reserve.
There is no evidence that lacidipine is useful for secondary prevention of myocardial infarction. The efficacy and safety of lacidipine in the treatment of malignant hypertension has not been established. Lacidipine should be used with caution in patients with impaired liver function because antihypertensive effect may be increased.
There is no evidence that lacidipine impairs glucose tolerance or alters diabetic control. This product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations